What patent protection does Synagis (palivizumab) have?
Synagis (palivizumab) is an antibody used to reduce the risk of serious respiratory syncytial virus (RSV) disease in certain children. Patent protection is meant to cover specific aspects of the product—such as the active ingredient, manufacturing, and/or particular methods of use. However, the exact scope and status depends on each individual patent in the relevant jurisdictions and how long those patents remain in force.
Is Synagis still under patent protection?
The key practical point is that “patent protection” can mean different things: the original drug’s basic patents, additional patents (such as formulation or method-of-use), and any exclusivity granted by regulators. Without the specific patent numbers, country, or date you mean, it’s not possible to state whether Synagis is currently protected, partially protected, or no longer protected.
When does a Synagis patent expire (and what affects that date)?
A patent’s expiration date can shift depending on:
- the filing/priority dates and whether the patent has term adjustments or extensions,
- jurisdiction-specific rules (for example, U.S. vs. EU vs. other countries),
- whether the company has additional “evergreen” patents tied to new claims (like updated dosing or subpopulations),
- whether regulatory exclusivity (not the patent) is still blocking generic/biosimilar entry.
Can a generic or biosimilar enter before Synagis patents expire?
In biologics, a generic version usually means a biosimilar. Entry often depends on the combination of patent status and regulatory exclusivity. If patents covering key claims are still in force, competitors may face legal barriers or be limited to non-infringing versions, depending on the legal strategy and claim scope.
Where to check Synagis patent status quickly (so you get the exact expiration)?
To answer your question precisely, you typically need at least one of the following:
- the country (e.g., U.S., EU, Canada, etc.),
- the specific patent number(s),
- the brand/generic naming and the referenced product in that jurisdiction,
- the approval application reference (e.g., for biosimilars/generics).
If you tell me which country (and, if you have it, the patent number or a link you’re looking at), I can help interpret what the patent covers and how that would affect market entry timing.
What side question people usually ask with “Synagis patent protection”?
- “Are there any biosimilars for palivizumab available or approved in my country?”
- “What patents are preventing them?”
- “Has the original protection already expired, and if so, what exclusivity remains?”
Reply with the country you mean (and whether you want the U.S. or EU specifically), and I’ll narrow it to the relevant Synagis/palivizumab protection and expected timelines.